Literature DB >> 35059804

Diagnostic validation of a deep learning nodule detection algorithm in low-dose chest CT: determination of optimized dose thresholds in a virtual screening scenario.

Alan A Peters1, Adrian T Huber2, Verena C Obmann2, Johannes T Heverhagen2,3,4, Andreas Christe2, Lukas Ebner2.   

Abstract

OBJECTIVES: This study was conducted to evaluate the effect of dose reduction on the performance of a deep learning (DL)-based computer-aided diagnosis (CAD) system regarding pulmonary nodule detection in a virtual screening scenario.
METHODS: Sixty-eight anthropomorphic chest phantoms were equipped with 329 nodules (150 ground glass, 179 solid) with four sizes (5 mm, 8 mm, 10 mm, 12 mm) and scanned with nine tube voltage/current combinations. The examinations were analyzed by a commercially available DL-based CAD system. The results were compared by a comparison of proportions. Logistic regression was performed to evaluate the impact of tube voltage, tube current, nodule size, nodule density, and nodule location.
RESULTS: The combination with the lowest effective dose (E) and unimpaired detection rate was 80 kV/50 mAs (sensitivity: 97.9%, mean false-positive rate (FPR): 1.9, mean CTDIvol: 1.2 ± 0.4 mGy, mean E: 0.66 mSv). Logistic regression revealed that tube voltage and current had the greatest impact on the detection rate, while nodule size and density had no significant influence.
CONCLUSIONS: The optimal tube voltage/current combination proposed in this study (80 kV/50 mAs) is comparable to the proposed combinations in similar studies, which mostly dealt with conventional CAD software. Modification of tube voltage and tube current has a significant impact on the performance of DL-based CAD software in pulmonary nodule detection regardless of their size and composition. KEY POINTS: • Modification of tube voltage and tube current has a significant impact on the performance of deep learning-based CAD software. • Nodule size and composition have no significant impact on the software's performance. • The optimal tube voltage/current combination for the examined software is 80 kV/50 mAs.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Artificial intelligence; Computer-assisted diagnosis; Deep learning; Lung neoplasms; Radiographic phantoms

Mesh:

Year:  2022        PMID: 35059804     DOI: 10.1007/s00330-021-08511-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  30 in total

1.  Performance of ultralow-dose CT with iterative reconstruction in lung cancer screening: limiting radiation exposure to the equivalent of conventional chest X-ray imaging.

Authors:  Adrian Huber; Julia Landau; Lukas Ebner; Yanik Bütikofer; Lars Leidolt; Barbara Brela; Michelle May; Johannes Heverhagen; Andreas Christe
Journal:  Eur Radiol       Date:  2016-01-26       Impact factor: 5.315

2.  Computed tomography of the chest with model-based iterative reconstruction using a radiation exposure similar to chest X-ray examination: preliminary observations.

Authors:  Angeliki Neroladaki; Diomidis Botsikas; Sana Boudabbous; Christoph D Becker; Xavier Montet
Journal:  Eur Radiol       Date:  2012-08-15       Impact factor: 5.315

3.  Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial.

Authors:  Eugenio Paci; Donella Puliti; Andrea Lopes Pegna; Laura Carrozzi; Giulia Picozzi; Fabio Falaschi; Francesco Pistelli; Ferruccio Aquilini; Cristina Ocello; Marco Zappa; Francesca M Carozzi; Mario Mascalchi
Journal:  Thorax       Date:  2017-04-04       Impact factor: 9.139

4.  Computer-aided detection (CAD) of solid pulmonary nodules in chest x-ray equivalent ultralow dose chest CT - first in-vivo results at dose levels of 0.13mSv.

Authors:  Michael Messerli; Thomas Kluckert; Meinhard Knitel; Fabian Rengier; René Warschkow; Hatem Alkadhi; Sebastian Leschka; Simon Wildermuth; Ralf W Bauer
Journal:  Eur J Radiol       Date:  2016-10-11       Impact factor: 3.528

5.  Randomized Study on Early Detection of Lung Cancer with MSCT in Germany: Results of the First 3 Years of Follow-up After Randomization.

Authors:  N Becker; E Motsch; M-L Gross; A Eigentopf; C P Heussel; H Dienemann; P A Schnabel; M Eichinger; D-E Optazaite; M Puderbach; M Wielpütz; H-U Kauczor; J Tremper; S Delorme
Journal:  J Thorac Oncol       Date:  2015-06       Impact factor: 15.609

6.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

7.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

8.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.

Authors:  Harry J de Koning; Carlijn M van der Aalst; Pim A de Jong; Ernst T Scholten; Kristiaan Nackaerts; Marjolein A Heuvelmans; Jan-Willem J Lammers; Carla Weenink; Uraujh Yousaf-Khan; Nanda Horeweg; Susan van 't Westeinde; Mathias Prokop; Willem P Mali; Firdaus A A Mohamed Hoesein; Peter M A van Ooijen; Joachim G J V Aerts; Michael A den Bakker; Erik Thunnissen; Johny Verschakelen; Rozemarijn Vliegenthart; Joan E Walter; Kevin Ten Haaf; Harry J M Groen; Matthijs Oudkerk
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 91.245

9.  Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer.

Authors:  David J Brenner
Journal:  Radiology       Date:  2004-05       Impact factor: 11.105

10.  Added Value of Ultra-low-dose Computed Tomography, Dose Equivalent to Chest X-Ray Radiography, for Diagnosing Chest Pathology.

Authors:  Lucia J M Kroft; Levinia van der Velden; Irene Hernández Girón; Joost J H Roelofs; Albert de Roos; Jacob Geleijns
Journal:  J Thorac Imaging       Date:  2019-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.